Biohaven Therapeutics Ltd.
Clinical trials sponsored by Biohaven Therapeutics Ltd., explained in plain language.
Biohaven Therapeutics Ltd.
BHVN
NYSE
A biopharmaceutical company focused on neuroscience and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug taldefgrobep alfa enters Mid-Stage trial Results expected Sep 2026 (estimated) May already have reported ↗
- New pill aims to tame seizures in Drug-Resistant epilepsy Results expected Oct 2026 (estimated) May already have reported ↗
- New hope for rare burning pain: drug trial targets genetic cause Results expected Nov 2026 (estimated) May already have reported ↗
- New epilepsy drug shows promise in reducing seizures Results expected Dec 2026 (estimated) May already have reported ↗
- New epilepsy drug safety check: 660 patients monitored long-term Results expected Dec 2026 (estimated) May already have reported ↗